### UNSCEAR PROJECT ON PUBLIC EXPOSURE

## APPLICATIONS OTHER THAN NUCLEAR POWER

**GLOBAL SURVEY** 

#### **VOLODYMYR BERKOVSKYY**

SUB-GROUP 6 LEAD WRITER

**UKRAINIAN RADIATION PROTECTION INSTITUTE** 

JNSCEAR WEBINAR FOR NATIONAL CONTACT PERSON

16 AND 24 MARCH 2021



### **SCOPE**

- Sources and levels of public exposure in medical applications (human and veterinary medicine)
  - nuclear medicine, radiation therapy, interventional radiology (fluoroscopy), diagnostic radiology, wearable medical devices, insertable (invasive)
    medical devices, dental products
- Sources and levels of public exposure due to applications in industry, agriculture and research, including consumer products (production, use and disposal):
  - Sources in industry, agriculture and research
    - Non-destructive testing and ensuring product quality (industrial fixed gauges, portable moisture and density gauges, industrial radiography cameras)
    - · Enhancing material quality
    - · Radioactive material in chemical industry as catalyst
    - Electrostatic control
    - · Radioactive tracers in industry and research
    - · Well logging devices, for example for oil and gas exploration
    - Agricultural applications (water use and soil management, pest control, plant and animal productivity, food safety)
    - · Radioisotope Thermoelectric Generators (RTG)
    - Security screening and non-medical body imaging (e.g. for legal purposes)
    - Other applications
  - Consumer products
    - Ionization chamber smoke detectors (ICSD)
    - Radioluminous products
    - High intensity discharge lamps
    - Fluorescent lamps starters
    - Electronic devices (voltage regulators, current surge protectors, spark gap irradiators and indicator lights)
    - Anti-static devices
    - Lightning preventors
    - · Thoriated incandescent gas mantles, lenses and tungsten welding electrodes
    - · Glassware, tableware, jewellery and ceramic tiles incorporating uranium
    - · Irradiated gemstones and other items
    - Antique products
- Sources and levels of public exposure due to research reactors and other large licensed facilities, such as accelerators

## ESSENTIAL DATA: LEVELS OF PUBLIC EXPOSURE (1)

#### 1. ESSENTIAL DATA: LEVELS OF PUBLIC EXPOSURE

1.1 Public exposure due to industrial, research and domestic applications of radioactive material and radiation generators in areas other than nuclear power sector and medicine

(E.g.: Members of the public exposed by authorised f	facilities, activiti	es and sources, or exposed by exe	mpted from regulatory control practic	ces and sources; Members of the public expo	osed by radioactive consumer products)		
	Estimated number of facilities or sources	Pathway of exposure	Type of exposed group of members of the public	Source- or pathway-specific estimates of annual effective dose to members of the public <sup>1</sup>	Estimated number of exposed members of the public in the country from all facilities of indicated type	Estimated annual collective effective dose from all facilities of indicated type	Estimated maximum tissue absorbed dose due to recorded accidental exposure of members of the public <sup>2</sup>
	[number]			[mSv]	[number]	[man-Sv]	[Gy]
(E.g.: Factory that produce high intensity discharge lamps with Th-232; OR Lightning preventors with Am-241 installed at end-users' facilities; OR Radioisotope Thermoelectric Generators with Sr-90 installed at end-users' facilities; OR Exempted from the regulatory control gaseous tritium light sources installed at end-users' facilities; OR Rapiscan Secure 1000 X-ray backscatter AIT in country's airports; OR Generic security X-ray body screening system; OR X-ray industrial imaging system);		(E.g.: Atmospheric (discharges); OR Communal sewer system (liquid discharges); OR External exposure; OR All pathways)	(E.g.: General public; OR Workers of communal sewer facility; OR Staff members and other individuals who are not categorised as occupationally exposed)	(E.g.: Actual data is 0.03 mSv per annum per consumer product; CR Actual data N/A, dose constraint is 0.1 mSv per annum of exposure per authorised source OR effective dose is about 25 nSv per screening; OR compliance with ANSI/IPS N43.17-2009 standard: reference effective dose 0.25 μSv per screening and 250 μSv/a)	(E.g.: Less than 30 000 individuals exposed above 10 µSv/y of the effective dose) OR 48 million passengers per annum screened in country's airports)	individuals exposed above 10 μSv/a is	(E.g.: Maximum absorbed dose of 0.8 Gy to the whole body due to accidental exposure of sixteen members of the public from the Cs-137 industrial sealed source melted with metal scrap)

## ESSENTIAL DATA: LEVELS OF PUBLIC EXPOSURE (2)

1.2 Public exposure due to medic	al application	ons, including veterina	rv medicine (does not in	nclude direct expo	sure. e.g. re	ceiving an x-ray)			
	ат арриоан	mo, moraumy rotorma	.,		ouro, orgini	conting an A ray,			
1.2.1 Doses to members of the public do	ue discharged	or disposed radioactive su	ubstances and due to extern	al exposure from rad	iation generate	ors			
Category of facility	Estimated number of facilities	Pathway of exposure	Type of exposed group of members of the public	Source- or pathwa estimates of annual of to members of the	effective dose members of the public in the		the effective dose from all facilities	Estimated maximum tissue absorbed dose due to recorded exposure of members of the public <sup>2</sup>	
	[number]			[mSv]		[number]	[man-Sv]	[Gy]	
(E.g.: Radioisotope production facility; OR Medical facilities that use radioisotopes; OR Radiotherapeutic facilities)	(E.g.: Radioisotope production facility; OR Medical (E.g.: Atmospheric (discharge facilities that use radioisotopes; OR OR Communal sewer syste				ers (E.g.: Estimated effective dose is 0.08 mSv (E.g.: 800 RP per annum to the most exposed individual usals from atmospheric discharges; Authorised discharge is 0.01 GBq of I-131 per month to per facility)		Sv/a) (E.g.: the collective effective dose of individuals exposed above 10 µSv/a is less than 1 man-Sv)		
1.2.2 Doses to members of the pu				n the body of pati	ents or dece	ased persons			
There are just examples in the categories	gories. Pleas	e feel free to provide you	ur own categories.						
Category an exposed group of mem	Category an exposed group of members of the public Estimates of effective dose to members of the public Estimated on members of the public in the country							ective effective dose	
			[mSv]			[number]	[man	-Sv]	
(E.g.: Members of the public other than family members, close friends, comforters or carers and exposed due to radionuclides in a patients body or excreta <sup>2</sup> ; OR Family and close friends)		e to exposed individ	(E.g.: Actual data N/A, constraint is 0.3 mSv to the most exposed individual per episode; OR Actual data N/A, effective dose constraint is 1 mSv to the unborn child per annum)			than 7 000 individuals d above 10 μSv/a)	(E.g.: An estimate of collective effe above 10 μ\$		

# SUPPLIMENTARY DATA: INVENTORIES OF RADOACTIVE MATERIAL AND SOURSES OF PUBLIC EXPOSURE

#### 2. SUPPLEMENTARY DATA: INVENTORY OF RADIOACTIVE MATERIAL AND SOURCES OF PUBLIC EXPOSURE

- 2.1 Public exposure due to industrial, research and domestic applications in areas other than nuclear power sector and medicine
- 2.1.1 Inventory of radioactive material in industrial, research and domestic applications

Radioactive material and type of	Year or period	Number of source	es in use (per annum) / total	Annual production (number of sources) /	Annual import (number of sources) /	Annual export (number of sources) / total
application			activity	total activity	total activity	activity
	[year-year]		[pcs/GBq]	[pcs/GBq]	[pcs/GBq]	[pcs/GBq]
(E.g.: Am-241 smoke detectors (indicate						
pcs of detectors if data on their activity are						
unavailable): OB tritium labelled						

2.1.2 Inventory of licenced large installations: research and other non-power reactors, particle accelerators, other large installations

Name of a facility or installation, type, key characteristics and location	Period of operation	Period of decommissioning		Facility- or pathway-specific estimates of annual public exposure <sup>1</sup>	Estimated number of exposed members of the public	Estimated annual collective effective dose
	[year-year]	[year-year]	[GBq]	[mSv]	[number of individuals]	[man-Sv]
(E.g.: VR-1, Training zero power pool-type light water reactor, usual power 1 kW, Technical University in city X)						

# SUPPLIMENTARY DATA: INVENTORIES OF RADOACTIVE MATERIAL AND SOURSES OF PUBLIC EXPOSURE

2. SUPPLEMENTARY DATA: INVENTORY OF RADIOACTIVE MATERIAL AND SOURCES OF PUBLIC EXPOSURE
2.1 Public exposure due to industrial, research and domestic applications in areas other than nuclear power sector and medicine

(E.g.: Co-60 source in therapeutic devices) (E.g.:2007-2020)

2.1.1 Inventory of radioactive mate	erial in industrial,	research and domestic app	plications							
Radioactive material and type of application	Year or period [year-year]	Number of sources in use (p activity [pcs/GBq]	per annum) / total Annual prod		umber of sources) / activity /GBq ]	Annual export (number activity				
(E.g.: Am-241 smoke detectors (indicate pcs of detectors if data on their activity are unavailable); OR tritium-labelled compounds)										
2.1.2 Inventory of licenced larg	ge installations	: research and other no	n-power reactors, partic	le accelerators, other large installation	ons					
Name of a facility or installation, ty key characteristics and location	rpe, Period operati		Annual discharges <sup>1,2</sup>	Facility- or pathway-specific estimates of annual public exposure <sup>1</sup>		number of exposed ers of the public	Estimated annual collective	effective dose		
	[year-ye	ear] [year-year]	[GBq]	[mSv]	[numb	er of individuals]	[man-Sv]			
(E.g.: VR-1, Training zero power pool- light water reactor, usual power 1 kW, Technical University in city X)										
	2.2 P	Public exposure due	to radioactive mate	erial in medical applications, in	ncluding vet	terinary medicine				
	224	Inventory of radioactive	substances for modica	I applications, including invasive m	odical davices					
	2.2.1	inventory or radioactive	s substances for medica	applications, including invasive in	edical devices					
		pharmaceutical or other ra		Year or period [year-year]	Ann	ual production (total act [GBq]	ivity) Annual import [GB		Annual export (total activi [GBq]	ity)
	(E.g	g.: I-125-fibrinogen; I-131-iod	ide; Ir-192 brachytherapy							
	2.2.2	Inventory of sealed s	ources in non-invasive	e medical devices						
	Radio	nuclide	Year or perio	d In use (per annum): total	activity	Annual pr total a		Annual import: total activity	Annual	export: total activ
			[vear-vear]	Inumber of sources/GI	Bal	Inumber of s		Inumber of sources/GB	al [num	ber of sources/GBal

(E.g.: average annual data for 2007-2020)

(E.g.: average annual data for 2007-

(E.g.: 12000 GBq / 15 pcs)

(E.g.: average annual data for 2007-2020)